Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy

Next Previous
Trial Profile

Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2018

At a glance

  • Drugs Palbociclib (Primary)
  • Indications Urogenital cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium
    • 20 Dec 2017 Planned End Date changed from 30 Jun 2018 to 17 Jul 2018.
    • 20 Dec 2017 Planned primary completion date changed from 1 Jul 2017 to 17 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top